Manufacturer of Controlled Substances; Notice of Registration, Cambrex Charles City, Inc., 43863 [2012-18209]
Download as PDF
<![CDATA[
43863
Federal Register / Vol. 77, No. 144 / Thursday, July 26, 2012 / Notices
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than September 24, 2012.
Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–18203 Filed 7–25–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Cambrex Charles City, Inc.
[FR Doc. 2012–18212 Filed 7–25–12; 8:45 am]
BILLING CODE 4410–09–P
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 4, 2012,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
TKELLEY on DSK3SPTVN1PROD with NOTICES
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
4-Anilino-N-phenethyl-4-piperidine
(ANPP)(8333).
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium, raw (9600) .......................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Poppy Straw Concentrate (9670)
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
I
II
II
II
II
II
II
II
II
II
II
II
II
16:42 Jul 25, 2012
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Boehringer Ingelheim Chemicals Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 8, 2012,
Boehringer Ingelheim Chemicals Inc.,
2820 N. Normandy Drive, Petersburg,
Virginia 23805–9372, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Schedule
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Tapentadol (9780) ........................
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Jkt 226001
DEPARTMENT OF JUSTICE
Drug
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers, for dosage form
development, for clinical trials, and for
use in stability qualification studies.
Any other such applicant, and any
person who is presently registered with
VerDate Mar<15>2010
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than September 24, 2012.
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers for formulation
into finished pharmaceuticals. In
reference to Methadone Intermediate
(9254) the company plans to produce
Methadone HCL active pharmaceutical
ingredients (APIs) for sale to its
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
PO 00000
Frm 00059
Fmt 4703
Sfmt 9990
Springfield, Virginia 22152; and must be
filed no later than September 24, 2012.
Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration
[FR Doc. 2012–18202 Filed 7–25–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration,
Cambrex Charles City, Inc.
By Notice dated April 17, 2012 and
published in the Federal Register on
April 26, 2012, 77 FR 24986, Cambrex
Charles City, Inc., 1205 11th Street,
Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Hydrocodone (9193) .....................
Methadone (9250) ........................
Schedule
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–18209 Filed 7–25–12; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\26JYN1.SGM
26JYN1
]]>Agencies
[Federal Register Volume 77, Number 144 (Thursday, July 26, 2012)]
[Notices]
[Page 43863]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-18209]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration,
Cambrex Charles City, Inc.
By Notice dated April 17, 2012 and published in the Federal
Register on April 26, 2012, 77 FR 24986, Cambrex Charles City, Inc.,
1205 11th Street, Charles City, Iowa 50616, made application by letter
to the Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Hydrocodone (9193)......................... II
Methadone (9250)........................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for sale to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a), and determined that the registration
of Cambrex Charles City, Inc. to manufacture the listed basic classes
of controlled substances is consistent with the public interest at this
time. DEA has investigated Cambrex Charles City, Inc. to ensure that
the company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-18209 Filed 7-25-12; 8:45 am]
BILLING CODE 4410-09-P
